Study Of The Effects Of Atorvastatin On Cholesterol Levels In Rheumatoid Arthritis Patients Taking CP-690,550

• Status: Completed
• Trial end date: 2010-11-01
• Target enrollment: 0
• Participant gender: All

Summary

All patients will be in instructed to eat a therapeutic lifestyle diet and will receive CP-690,550 throughout the 12 weeks of this study. After 6 weeks, half will receive the cholesterol lowering agent, atorvastatin, and half a matching placebo. This study will first measure the effects of CP-690,550 on cholesterol levels and then the effects of adding atorvastatin on those levels.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Atorvastatin; Atorvastatin Calcium; Tofacitinib

Criteria

Inclusion Criteria:

• must be diagnosed as having active rheumatoid arthritis

• agree to participate in the study and sign and informed consent document

Exclusion Criteria:

• History of serious infection within the past 6 months

• test positive for TB

• have any uncontrolled clinically significant disease or laboratory tests

• require administration of prohibited medications during the study